<?xml version='1.0' encoding='utf-8'?>
<document id="21873472"><sentence text="Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics." /><sentence text="The preclinical absorption, distribution, metabolism, and excretion (ADME) properties of Pracinostat [(2E)-3-[2-butyl-1-[2-(diethylamino) ethyl]-1H-benzimidazol-5-yl]-N-hydroxyarylamide hydrochloride; SB939], an orally active histone deacetylase inhibitor, were characterized and its human pharmacokinetics (PK) was predicted using Simcyp and allometric scaling"><entity charOffset="89-199" id="DDI-PubMed.21873472.s2.e0" text="Pracinostat [(2E)-3-[2-butyl-1-[2-(diethylamino) ethyl]-1H-benzimidazol-5-yl]-N-hydroxyarylamide hydrochloride" /></sentence><sentence text=" SB939 showed high aqueous solubility with high Caco-2 permeability" /><sentence text=" Metabolic stability was relatively higher in dog and human liver microsomes than in mouse and rat" /><sentence text=" The major metabolites formed in human liver microsomes were also observed in preclinical species" /><sentence text=" Human cytochrome P450 (P450) phenotyping showed that SB939 was primarily metabolized by CYP3A4 and CYP1A2" /><sentence text=" SB939 did not significantly inhibit human CYP3A4, 1A2, 2D6, and 2C9 (&gt;25 μM) but inhibited 2C19 (IC(50) = 5" /><sentence text="8 μM)" /><sentence text=" No significant induction of human CYP3A4 and 1A2 was observed in hepatocytes" /><sentence text=" Plasma protein binding in mouse, rat, dog, and human ranged between ∼84 and 94%" /><sentence text=" The blood-to-plasma ratio was ∼1" /><sentence text="0 in human blood" /><sentence text=" SB939 showed high systemic clearance (relative to liver blood flow) of 9" /><sentence text="2, 4" /><sentence text="5, and 1" /><sentence text="5 l · h(-1) · kg(-1) and high volume of distribution at steady state (&gt;0" /><sentence text="6 l/kg) of 3" /><sentence text="5, 1" /><sentence text="7, and 4" /><sentence text="2 l/kg in mouse, rat, and dog, respectively" /><sentence text=" The oral bioavailability was 34, 65, and ∼3% in mice, dogs, and rats, respectively" /><sentence text=" The predicted oral PK profile and parameters of SB939, using Simcyp and allometric scaling, were in good agreement with observed data in humans" /><sentence text=" Simcyp predictions showed lack of CYP3A4 and 2C19 drug-drug interaction potential for SB939" /><sentence text=" In summary, the preclinical ADME of SB939 supported its preclinical and clinical development as an oral drug candidate" /><sentence text="" /></document>